240 related articles for article (PubMed ID: 24318989)
1. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
3. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
4. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.
Li J; Zuo X; Lv X; Kong F; Xu W; Yang S
Tumour Biol; 2014 Aug; 35(8):7569-74. PubMed ID: 24793015
[TBL] [Abstract][Full Text] [Related]
5. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer.
Chen ZH; Wang L; Luo LP
Genet Mol Res; 2014 Sep; 13(3):7484-91. PubMed ID: 25222248
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Zhong G; Li HK; Shan T; Zhang N
Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
[TBL] [Abstract][Full Text] [Related]
11. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
Gao H; Ge RC; Liu HY; Wang Y; Yan S
Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
13. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
14. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
17. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]